Yakov Kogan

Dr. Kogan is a seasoned executive with an exemplary track record of business development and fundraising. Prior to joining Cytocom, Inc. in 2021, Dr. Yakov led operations at GPI, Dr. Kogan served as a CEO and director of Cleveland BioLabs (NASDAQ: CBLI) where he had built the company up from its inception to an operation with over 50 full-time employees, while securing upward of $150 million in equity financing at highly attractive valuations. He was also responsible for securing federal and state grants totaling more than $65 million. In his tenure with CBLI, Dr. Kogan played a significant role in establishing operations, hiring senior operations staff and executing the Company’s initial public offering on NASDAQ.

Prior to CBLI, Dr. Kogan served as Director for Business Development at Integrated Genomics in Chicago, IL, where he was responsible for commercial sales and expansion of the company’s capital base. Dr. Kogan closed several complex international deals and expanded contracts with governmental research laboratories, representing more than one-third of total sales. Prior to his tenure in business development, Dr. Kogan worked as a Group Leader/Senior Scientist at Integrated Genomics and at ThermoGen, Inc. and as Research Associate at the University of Chicago, where he led the execution of several sophisticated genome sequencing projects.

Dr. Kogan holds a Ph.D. degree in Molecular Biology from VNII Genetica, as well as an M.S. degree in Biology from Moscow State University and an MBA from the University of Chicago.